Challenges and reforms in Spain’s health technology assessment system: analysis of criteria influencing medicines’ reimbursement decisions between 2019 and 2022 in Spain
Open Access
- 9 May 2025
- journal article
- research article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 26 (9) , 1569-1579
Abstract
Objective: To analyse the criteria influencing medicines’ reimbursement decisions in the Spanish National Health Service and assess the extent to which these decisions have been supported by health technology assessment (HTA), considering the ongoing HTA reform. Materials and methods: The sample includes all new medicines and new indications undergoing reimbursement between May 2019 and December 2022 in Spain. Criteria influencing the decision were derived from the Interministerial Pricing Committee for Medicines’ reports. These were matched with the HTA reports obtained from the Spanish Medicines Agency’s website. Spanish decisions are compared to those in France and England. The analyses include descriptive analysis, association statistical tests, sentiment text analysis, keyword extraction, decision analysis, and clustering. Results: Out of 477 therapeutic indications, 253 could be matched to a HTA report. Positive recommendations ( n = 110) were statistically significantly associated with severity and therapeutic value (including clinical and cost effectiveness) criteria, whereas negative recommendations ( n = 143) were mostly associated with criteria based on budget impact and availability of a cheaper alternative option ( p < 0.05). The innovation criterion was not used to support any decision. Only 9.49% of reimbursement reports mentioned the HTA in the conclusions, and 21.74% of the HTAs included keywords aligned with the specific decision-making criteria. Conclusion: The criteria used to justify the reimbursement decisions of medicines in Spain do not align with the information included in the HTA. This discrepancy highlights the need for the ongoing HTA reform to develop an appraisal framework that aligns with the HTA assessment in a transparent, rigorous, and inclusive manner.Keywords
Funding Information
- Universidad de Las Palmas de Gran Canaria
This publication has 25 references indexed in Scilit:
- Guideline for the economic evaluation of medicines: a proposal by the Spanish National Health System's Advisory Committee for Pharmaceutical FinancingGaceta Sanitaria, 2025
- Reform of economic evaluation of medicines in Spain: proposals from the Advisory Committee for Pharmaceutical FinancingGaceta Sanitaria, 2025
- Propuestas concretas para organizar una agencia de evaluación de la eficiencia de tecnologías y políticas sanitariasGaceta Sanitaria, 2024
- Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursementThe European Journal of Health Economics, 2023
- Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 CountriesPharmacoEconomics - Open, 2021
- Evaluation of new medicines in Spain and comparison with other European countriesGaceta Sanitaria, 2020
- HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?The European Journal of Health Economics, 2019
- An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?The European Journal of Health Economics, 2019
- Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved DrugsClinical Pharmacology & Therapeutics, 2018
- Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countriesThe European Journal of Health Economics, 2017